EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced it will host a conference call and webcast on Wednesday, March 23, 2022, at 8:00 a.m. ET to report its fourth quarter and full year 2021 financial results and provide a business update.
A live webcast can be accessed by visiting the Investors section of the Company’s website at investors.eqrx.com. The conference call can be accessed by dialing 855-718-8094 (domestic) or 484-747-6788 (international) and referring to conference ID 4596972. The webcast will be made available for replay on the Company's website beginning approximately two hours after the event.
About EQRx
EQRx is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices. Launched in January 2020, EQRx is purpose-built, at scale, with a growing catalog of medicines in development in high-cost drug categories and emerging partnerships with leading payers and providers. Leveraging cutting-edge science and technology and strategic partnerships with stakeholders from across the healthcare system, EQRx aims to provide innovative, patent-protected medicines more efficiently and cost-effectively than ever before. To learn more, visit www.eqrx.com and follow us on social media: Twitter: @EQRxInc, LinkedIn, Instagram: @eqrxinc.
EQRx™ and Remaking Medicine™ are trademarks of EQRx.
EQRx Contacts:
Media:
Dan Budwick
1AB
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors:
This email address is being protected from spambots. You need JavaScript enabled to view it.
February 23, 2023 December 02, 2022 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load